Israeli biopharmaceutical company BioLineRX Ltd said on Wednesday an early stage trial for a drug that uses stem cells to treat leukemia and other blood cancers met all safety and efficacy goals. Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its treatment, currently called BL-8040, needed just one. "The results exceeded our expectations, and validate BL-8040 as a highly differentiated stand-alone treatment for stem-cell collection," said Kinneret Savitsky, BioLineRx's chief executive. She said the company planned to meet with the U.S. Food and Drug Administration as soon as practicable to discuss the results of this study and obtain more clarity on the next steps in the clinical development program for this treatment. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment